| Citation: |
CHEN Yufan, LI Sicong, CUI Yiyuan, FENG Li. Research Progress of Fuzheng Jiedu Huayu Method in Reducing Toxicity and Enhancing Efficacy of Immunotherapy[J]. Cancer Research on Prevention and Treatment, 2025, 52(1): 11-18. DOI: 10.3971/j.issn.1000-8578.2025.24.0839
|
Immunotherapy, including immune checkpoint inhibitors, tumor vaccine therapy, oncolytic virotherapy, and adoptive cell therapy, has made remarkably breakthroughs in the field of oncology. Immune checkpoint inhibitors, which block programmed death receptor 1 or programmed death ligand 1, have been included in the first-line clinical treatment for advanced solid tumors, such as non-small cell lung cancer and malignant melanoma. However, primary or secondary drug resistance in tumors severely limits the survival benefits for patients. Immune-related adverse reactions, such as pneumonia, hypothyroidism, hypophysitis, and myocarditis, also greatly affect the quality of life of patients. Fuzheng Jiedu Huayu is an important concept guiding the prevention and treatment of tumors with traditional Chinese medicine (TCM). It is also a curative principle and therapeutic TCM method to reduce the toxicity and enhance the efficacy of immunotherapy. This article summarizes the research progress of immunotherapy and discusses how TCM reduces the toxicity and enhances the efficacy of immunotherapy, hoping to provide a reference for the integrated treatment of tumors with TCM and immunotherapy.
Competing interests: The authors declare that they have no competing interests.
| [1] |
Qi J, Li M, Wang L, et al. National and subnational trends in cancer burden in China, 2005-20: an analysis of national mortality surveillance data[J]. Lancet Public Health, 2023, 8(12): e943-e955. doi: 10.1016/S2468-2667(23)00211-6
|
| [2] |
Ai L, Chen J, Yan H, et al. Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy[J]. Drug Des Devel Ther, 2020, 14: 3625-3649.
|
| [3] |
Jogalekar MP, Rajendran RL, Khan F, et al. CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments[J]. Front Immunol, 2022, 13: 925985. doi: 10.3389/fimmu.2022.925985
|
| [4] |
Blass E, Ott PA. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines[J]. Nat Rev Clin Oncol, 2021, 18(4): 215-229.
|
| [5] |
Shalhout SZ, Miller DM, Emerick KS, et al. Therapy with oncolytic viruses: progress and challenges[J]. Nat Rev Clin Oncol, 2023, 20(3): 160-177. doi: 10.1038/s41571-022-00719-w
|
| [6] |
Agata Y, Kawasaki A, Nishimura H, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes[J]. Int Immunol, 1996, 8(5): 765-772. doi: 10.1093/intimm/8.5.765
|
| [7] |
Shiratori T, Miyatake S, Ohno H, et al. Tyrosinephosphorylation controls internalization of CTLA-4 by regulating its interaction with clathrin-associated adaptor complex AP-2[J]. Immunity, 1997, 6(5): 583-589.
|
| [8] |
Wei SC, Levine JH, Cogdill AP, et al. Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade[J]. Cell, 2017, 170(6): 1120-1133,e17. doi: 10.1016/j.cell.2017.07.024
|
| [9] |
Ferris R, Gillison ML. Nivolumab for squamous-cell cancer of head and neck[J]. N Engl J Med, 2017, 376(6): 596. doi: 10.1056/NEJMc1616177
|
| [10] |
Vaddepally RK, Kharel P, Pandey R, et al. Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence[J]. Cancers (Basel), 2020, 12(3): 738. doi: 10.3390/cancers12030738
|
| [11] |
Cameron F, Whiteside G, Perry C. Ipilimumab: first global approval[J]. Drugs, 2011, 71(8): 1093-1104. doi: 10.2165/11594010-000000000-00000
|
| [12] |
Joseph GJ, Johnson DB, Johnson RW. Immune checkpoint inhibitors in bone metastasis: Clinical challenges, toxicities, and mechanisms[J]. J Bone Oncol, 2023, 43: 100505.
|
| [13] |
Lee DY, Im E, Yoon D, et al. Pivotal role of PD- 1/PD-L1 immune checkpoints in immune escape and cancer progression: their interplay with platelets and FOXP3+ Tregs related molecules, clinical implications and combinational potential with phytochemicals[J]. Semin Cancer Biol, 2022, 86(Pt 3): 1033-1057.
|
| [14] |
朱波. 肿瘤免疫治疗耐药机制与克服策略[J]. 中国肿瘤生物治疗杂志, 2023, 30(3): 187-195. [Zhu B. Mechanism and respone strategies of resistance in tumor immunotherapy[J]. Zhongguo Zhong Liu Sheng Wu Zhi Liao Za Zhi, 2023, 30(3): 187-195.] doi: 10.3872/j.issn.1007-385X.2023.03.001
Zhu B. Mechanism and respone strategies of resistance in tumor immunotherapy[J]. Zhongguo Zhong Liu Sheng Wu Zhi Liao Za Zhi, 2023, 30(3): 187-195. doi: 10.3872/j.issn.1007-385X.2023.03.001
|
| [15] |
史伟伟, 张璐, 武艺铭, 等. 中医正邪理论与肿瘤免疫疗法辩证关系研究[J/OL]. 辽宁中医杂志, 2024: 1-7. [2024-07-13]. [Shi WW, Zhang L, Wu YM, et al. Study on the dialectical relationship between TCM theoryand tumor immunotherapy[J/OL]. Liaoning Zhong Yi Za Zhi, 2024: 1-7. [2024-07-13]. http://kns.cnki.net/kcms/detail/21.1128.R.20240710.0750.006.html.
|
| [16] |
唐淑慧, 凤美娟, 薛智霞, 等. 帕博利珠单抗治疗所致免疫相关不良反应与中医体质的相关性研究[J]. 药学实践与服务, 2024, 42(5): 217-222. [Tang SH, Feng MJ, Xue ZX, et al. Correlation between immune related adverse reactions in patients treated with pembrolizumab and Traditional Chinese Medicine constitution[J]. Yao Xue Shi Jian Yu Fu Wu, 2024, 42(5): 217-222.] doi: 10.12206/j.issn.2097-2024.202311029
Tang SH, Feng MJ, Xue ZX, et al. Correlation between immune related adverse reactions in patients treated with pembrolizumab and Traditional Chinese Medicine constitution[J]. Yao Xue Shi Jian Yu Fu Wu, 2024, 42(5): 217-222. doi: 10.12206/j.issn.2097-2024.202311029
|
| [17] |
陈晨, 贾立群, 娄彦妮, 等. 免疫检查点抑制剂相关性肺炎发病及治疗的中医思考[J]. 中国中医急症, 2022, 31(3): 425-428,432. [Chen C, Jia LQ, Lou YN, et al. Pathogenesis Analysis and Treatment Exploration in Traditional Chinese Medicine of Immune Check-point Inhibitor-related Pneumonitis[J]. Zhongguo Zhong Yi Ji Zheng, 2022, 31(3): 425-428,432.] doi: 10.3969/j.issn.1004-745X.2022.03.013
Chen C, Jia LQ, Lou YN, et al. Pathogenesis Analysis and Treatment Exploration in Traditional Chinese Medicine of Immune Check-point Inhibitor-related Pneumonitis[J]. Zhongguo Zhong Yi Ji Zheng, 2022, 31(3): 425-428,432. doi: 10.3969/j.issn.1004-745X.2022.03.013
|
| [18] |
Chen SY, Zhao FM, Yu R, et al. Clinical Experience of External Application of Clearing Heat and Removing Dampness in Relieving Grade 2 to 3 Rash Caused by Programed Cell Death Protein 1 (PD-1)/Programed Cell Death Ligand 1 (PD-L1) Inhibitors: A Single-Center Retrospective Study[J]. Integr Cancer Ther, 2024, 23: 15347354231226108.
|
| [19] |
李子欣. 免疫检查点抑制剂引起皮肤毒性的影响因素及滋阴消疹方对其干预的研究[D]. 天津: 天津中医药大学, 2023. [Li ZX. Factors Influencing Skin Toxicity Caused By Immune Checkpoint Inhibitors and the Intervention of Nourishing Yin and Eliminating Rash Formula on It[D]. Tianjin: Tianjin University of Traditional Chinese Medicine, 2023.]
Li ZX. Factors Influencing Skin Toxicity Caused By Immune Checkpoint Inhibitors and the Intervention of Nourishing Yin and Eliminating Rash Formula on It[D]. Tianjin: Tianjin University of Traditional Chinese Medicine, 2023.
|
| [20] |
苏悦. 解毒清疹方治疗PD-1单抗致风热疮疗效及安全性的临床研究[D]. 长春: 长春中医药大学, 2022. [Su Y. A Clinical Study on the Efficacy and Safety of Jiedu Qingchen Formula in Treating Pemphigus Vulgaris Induced by PD-1 Antibody[J]. Changchun: Changchun University of Chinese Medicine, 2022.]
Su Y. A Clinical Study on the Efficacy and Safety of Jiedu Qingchen Formula in Treating Pemphigus Vulgaris Induced by PD-1 Antibody[J]. Changchun: Changchun University of Chinese Medicine, 2022.
|
| [21] |
司一含. 加味升阳益胃散治疗恶性肿瘤免疫相关腹泻的临床研究[D]. 长春: 长春中医药大学, 2023. [Si YH. A Clinical Study on the Treatment of Malignant Tumor-Related Immune Diarrhea with Modified Yangsheng Yigan Powder[J]. Changchun: Changchun University of Chinese Medicine, 2023.]
Si YH. A Clinical Study on the Treatment of Malignant Tumor-Related Immune Diarrhea with Modified Yangsheng Yigan Powder[J]. Changchun: Changchun University of Chinese Medicine, 2023.
|
| [22] |
时红萍, 刘洪敬, 黄姝, 等. 柴胡桂枝汤加减治疗PD-1/PD-L1抑制剂治疗肿瘤后腹泻的临床研究[J]. 系统医学, 2022, 7(15): 17-22,45. [Shi HP, Liu HJ, Huang S, et al. Clinical Study of Modified Chaihu Guizhi Decoction in the Treatment of PD-1/PD-L1 Inhibitor for Post-tumor Diarrhea[J]. Xi Tong Yi Xue, 2022, 7(15): 17-22,45.]
Shi HP, Liu HJ, Huang S, et al. Clinical Study of Modified Chaihu Guizhi Decoction in the Treatment of PD-1/PD-L1 Inhibitor for Post-tumor Diarrhea[J]. Xi Tong Yi Xue, 2022, 7(15): 17-22,45.
|
| [23] |
赵欢, 吕鹏, 李亚, 等. 乌梅丸对肿瘤免疫治疗相关结肠炎大鼠IL-1β、NF-κB、Foxp3影响的研究[C]//中国中西医结合学会肿瘤专业委员会. 第十七届全国中西医结合肿瘤学术大会摘要集. 2019: 2. [Zhao H, Lyu P, Li Y, et al. The study on the effects of Wumei Pill on IL-1β, NF-κB, and Foxp3 in rats with colitis related to tumor immunotherapy[C]// Chinese Society of Integrative Oncology, Specialized Committee of Oncology. Abstracts of the 17th National Academic Conference on Integrative Oncology. 2019: 2.]
Zhao H, Lyu P, Li Y, et al. The study on the effects of Wumei Pill on IL-1β, NF-κB, and Foxp3 in rats with colitis related to tumor immunotherapy[C]// Chinese Society of Integrative Oncology, Specialized Committee of Oncology. Abstracts of the 17th National Academic Conference on Integrative Oncology. 2019: 2.
|
| [24] |
郭环宇, 李明晶, 王博, 等. 芍药汤加味治疗肠道湿热型免疫相关性结肠炎的疗效[J]. 中国老年学杂志, 2023, 43(13): 3132-3135. [Guo HY, Li MJ, Wang B, et al. The therapeutic efficacy of the modified Shaoyao Decoction in treating damp-heat typeimmune-related colitis in the intestines[J]. Zhong Guo Lao Nian Xue Za Zhi, 2023, 43(13): 3132-3135.] doi: 10.3969/j.issn.1005-9202.2023.13.016
Guo HY, Li MJ, Wang B, et al. The therapeutic efficacy of the modified Shaoyao Decoction in treating damp-heat typeimmune-related colitis in the intestines[J]. Zhong Guo Lao Nian Xue Za Zhi, 2023, 43(13): 3132-3135. doi: 10.3969/j.issn.1005-9202.2023.13.016
|
| [25] |
李沅耕. Lewis肺癌和/或PD-1单抗加重小鼠免疫性肝炎的机制及人参皂苷Rd的干预作用[D]. 长春: 吉林大学, 2023. [Li Y. Mechanism of Immune Hepatitis aggravated byLewis lung Cancer and/or anti-PD-1 in Mice andthe Interventive Effect ofGinsenoside Rd[D]. Changchun: Jilin University, 2023.]
Li Y. Mechanism of Immune Hepatitis aggravated byLewis lung Cancer and/or anti-PD-1 in Mice andthe Interventive Effect ofGinsenoside Rd[D]. Changchun: Jilin University, 2023.
|
| [26] |
姚生旺. 芪归补血糖浆对肺脾气虚型非小细胞肺癌免疫治疗后癌因性疲乏的临床观察[D]. 承德: 承德医学院, 2023. [Yao SW. Clinical Observation of Qigui Buxue Syrup On Cancer-Related Fatigue After Immunotherapy for Non-small Cell Lung Cancer of Lung-Spleen Deficiency Type[D]. Chengde: Chengde Medical University, 2023.]
Yao SW. Clinical Observation of Qigui Buxue Syrup On Cancer-Related Fatigue After Immunotherapy for Non-small Cell Lung Cancer of Lung-Spleen Deficiency Type[D]. Chengde: Chengde Medical University, 2023.
|
| [27] |
周丹, 谢磊. 桂枝茯苓丸联合PD-1治疗晚期卵巢癌的临床研究[J]. 实用妇科内分泌电子杂志, 2024, 11(2): 68-70. [Zhou D, Xie L. Clinical study of guizhi fuling pill combined with PD-1 in the treatment of advanced ovarian cancer[J]. Shi Yong Fu Ke Nei Fen Mi Dian Zi Za Zhi, 2024, 11(2): 68-70.]
Zhou D, Xie L. Clinical study of guizhi fuling pill combined with PD-1 in the treatment of advanced ovarian cancer[J]. Shi Yong Fu Ke Nei Fen Mi Dian Zi Za Zhi, 2024, 11(2): 68-70.
|
| [28] |
张静娴. 参芪扶正注射液联合恩度及PD-1抑制剂治疗驱动基因阴性非小细胞肺癌的临床研究[D]. 天津: 天津中医药大学, 2023. [Zhang JX. Clinical study of Shenqi Fuzheng injection combined with endostar and PD-1 inhibitor in the treatment of driver gene negative NSCLC[D]. Tianjin: Tianjin University of Traditional Chinese Medicine, 2023.]
Zhang JX. Clinical study of Shenqi Fuzheng injection combined with endostar and PD-1 inhibitor in the treatment of driver gene negative NSCLC[D]. Tianjin: Tianjin University of Traditional Chinese Medicine, 2023.
|
| [29] |
Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Prolonged survival in stage Ⅲ melanoma with ipilimumab adjuvant therapy[J]. N Engl J Med, 2016, 375(19): 1845-1855. doi: 10.1056/NEJMoa1611299
|
| [30] |
Phillips GS, Wu J, Hellmann MD, et al. Treatment outcomes of immune-related cutaneous adverse events[J]. J Clin Oncol, 2019, 37(30): 2746-2758.
|
| [31] |
彭艳梅, 张静怡, 崔慧娟, 等. 基于网络药理学分析止痒平肤液治疗靶向药相关皮疹和皮肤瘙痒的分子机制[J]. 中医杂志, 2018, 59(19): 1674-1678. [Peng YM, Zhang JY, Cui HJ, et al. Analysis of the Molecular Mechanism of Zhiyang Pingfu Decoction in the Treatment of Targeted Drugs-related Skin Rash and Pruritus: based on Network Pharmacology[J]. Zhong Yi Za Zhi, 2018, 59(19): 1674-1678.]
Peng YM, Zhang JY, Cui HJ, et al. Analysis of the Molecular Mechanism of Zhiyang Pingfu Decoction in the Treatment of Targeted Drugs-related Skin Rash and Pruritus: based on Network Pharmacology[J]. Zhong Yi Za Zhi, 2018, 59(19): 1674-1678.
|
| [32] |
魏桐, 李羽新, 陈婕, 等. 痛泻要方对肝郁脾虚型肠易激综合症大鼠CRH-R1表达和肥大细胞的影响[J]. 山西中医, 2020, 36(7): 52-54,57. [Wei T, Li YX, Chen J, et al. Effect of Tongxie Yaofang on CRH-R1 expression and mast cells of IBS-D rat with liver-depression and spleen-deficiency syndrome[J]. Shanxi Zhong Yi, 2020, 36(7): 52-54,57.] doi: 10.3969/j.issn.1000-7156.2020.07.023
Wei T, Li YX, Chen J, et al. Effect of Tongxie Yaofang on CRH-R1 expression and mast cells of IBS-D rat with liver-depression and spleen-deficiency syndrome[J]. Shanxi Zhong Yi, 2020, 36(7): 52-54,57. doi: 10.3969/j.issn.1000-7156.2020.07.023
|
| [33] |
Liang Y, Li S, Zheng G, et al. beta-elemene suppresses the malignant behavior of esophageal cancer cells by regulating the phosphorylation of AKT[J]. Acta Histochem, 2020, 122(4): 151538. doi: 10.1016/j.acthis.2020.151538
|
| [34] |
Quan YS, Zhang XY, Yin XM, et al. Potential alpha-glucosidase inhibitor from Hylotelephium erythrostictum[J]. Bioorg Med Chem Lett, 2020, 30(24): 127665. doi: 10.1016/j.bmcl.2020.127665
|
| [35] |
Wang W, Kong M, Shen F, et al. Ginsenoside Rg3 targets glycosylation of PD-L1 to enhance anti-tumor immunity in non-small cell lung cancer[J]. Front Immunol, 2024, 15: 1434078.
|
| [36] |
Teng L, Wang K, Chen W, et al. HYR-2 plays an anti-lung cancer role by regulating PD-L1 and Akkermansia muciniphila[J]. Pharmacol Res, 2020, 160: 105086. doi: 10.1016/j.phrs.2020.105086
|
| [37] |
Yang R, Pei T, Huang R, et al. Platycodon grandiflorum Triggers Antitumor Immunity by Restricting PD-1 Expression of CD8+ T Cells in Local Tumor Microenvironment[J]. Front Pharmacol, 2022, 13: 774440. doi: 10.3389/fphar.2022.774440
|
| [38] |
谭倩影, 谢贵萍, 李响, 等. 黄芪四君子汤调节T细胞PD1泛素化水平重塑肿瘤免疫微环境抑制胃癌增殖的研究[J]. 南京中医药大学学报, 2023, 39(7): 629-636. [Tan QY, Xie GP, Li X, et al. Huangqi Sijunzi Decoction Restrained Gastric Cancer Proliferation via Regulating the Level of PD1 Ubiquitination on T Cells and Remodeling the Tumor Immune Microenvironment[J]. Nanjing Zhong Yi Yao Da Xue Xue Bao, 2023, 39(7): 629-636.]
Tan QY, Xie GP, Li X, et al. Huangqi Sijunzi Decoction Restrained Gastric Cancer Proliferation via Regulating the Level of PD1 Ubiquitination on T Cells and Remodeling the Tumor Immune Microenvironment[J]. Nanjing Zhong Yi Yao Da Xue Xue Bao, 2023, 39(7): 629-636.
|
| [39] |
梁颖, 程钢, 黄邓高. 益脾活血方调控B7-H1/PD-1通路对大鼠肝癌切除术后防止复发的机制研究[J]. 四川中医, 2019, 37(8): 24-28. [Liang Y, Cheng G, Huang DG. Preventive Mechanism of Yipi Huoxue Recipe on Postoperative Recurrence for Rats after Hepatectomy by Regulating B7-H1/PD-1 Signal Pathway[J]. Sichuan Zhong Yi, 2019, 37(8): 24-28.]
Liang Y, Cheng G, Huang DG. Preventive Mechanism of Yipi Huoxue Recipe on Postoperative Recurrence for Rats after Hepatectomy by Regulating B7-H1/PD-1 Signal Pathway[J]. Sichuan Zhong Yi, 2019, 37(8): 24-28.
|
| [40] |
Mao D, Feng L, Gong H. The antitumor and immunomodulatory effect of Yanghe Decoction in breast cancer is related to the modulation of the JAK/STAT signaling pathway[J]. Evid Based Complement Alternat Med, 2018, 2018: 8460526. doi: 10.1155/2018/8460526
|
| [41] |
Yang K, Blanco DB, Neale G, et al. Homeostatic control of metabolic and functional fitness of Treg cells by LKB 1 signalling[J]. Nature, 2017, 548(7669): 602-606. doi: 10.1038/nature23665
|
| [42] |
Pang LN, Han SY, Mao YN, et al. Bu Fei Decoction attenuates the tumor associated macrophage stimulated proliferation, migration, invasion and immunosuppression of non-small cell lung cancer, partially via IL-10 and PD-L1 regulation[J]. Int J Oncol, 2017, 51(1): 25-38. doi: 10.3892/ijo.2017.4014
|
| [1] | WANG Zhigao, FANG Qiqi, GAO Fei, LI Qingxia. Mechanism and Strategy of Combination Immunotherapy in Integrated Tumor Therapy[J]. Cancer Research on Prevention and Treatment, 2020, 47(11): 818-816. DOI: 10.3971/j.issn.1000-8578.2020.19.1400 |
| [2] | SHEN Wenbin, GAO Hongmei, ZHU Shuchai, LI Teng, LI Shuguang, LI Youmei, LIU Zhikun, LI Juan, SU Jingwei. Salvage Therapy for Post-operative Local Recurrence or Metastasis in Stage pT1-3N0M0 of Thoracic Esophageal Squamous Cell Carcinoma[J]. Cancer Research on Prevention and Treatment, 2017, 44(10): 672-676. DOI: 10.3971/j.issn.1000-8578.2017.17.0178 |
| [3] | CUI Ya, JIANG Lishuang, BU Ping. Recent Progress in Treatment of Esophageal Gastroiontestinal Stromal Tumors[J]. Cancer Research on Prevention and Treatment, 2017, 44(4): 303-307. DOI: 10.3971/j.issn.1000-8578.2017.04.014 |
| [4] | LI Xiaofen, YUAN Ying. Individualized Treatment for Advanced Colorectal Cancer Patients Based on Molecular Characteristics[J]. Cancer Research on Prevention and Treatment, 2015, 42(09): 924-928. DOI: 10.3971/j.issn.1000-8578.2015.09.014 |
| [5] | ZHANG Yanli, ZHU Shunqin, LIU Yaling, CUI Hongjuan. 恶性黑色素瘤内科治疗研究进展[J]. Cancer Research on Prevention and Treatment, 2014, 41(01): 74-78. DOI: 10.3971/j.issn.1000-8578.2014.01.017 |
| [6] | ZENG Ming, DONG Yang. Surgical Treatment of Recurrent Giant Cell Tumors of Bone[J]. Cancer Research on Prevention and Treatment, 2007, 34(08): 614-617. DOI: 10.3971/j.issn.1000-8578.151 |
| [7] | YANG Zhi xiong, LIANG Rong, HUANG Jie, et al, . The analysis of treatment with radiothyropy and chemothyropy to old patients with Non-small cell lung cancer[J]. Cancer Research on Prevention and Treatment, 2003, 30(03): 228-230. DOI: 10.3971/j.issn.1000-8578.2718 |
| [8] | WANG Rui, SUN Li, KANG Jing-bo, et al, . The treatment of the radiation damage after brain tumor patient radiotherapy[J]. Cancer Research on Prevention and Treatment, 2002, 29(05): 391-393. DOI: 10.3971/j.issn.1000-8578.1798 |
| [9] | SONG Qi-bin, HU De-sheng, ZHOU Xiao-yi, et al, . Radiation therapy combined with chemotherapy for locally advanced nasopharyngeal carcinoma[J]. Cancer Research on Prevention and Treatment, 2002, 29(04): 339-340. DOI: 10.3971/j.issn.1000-8578.3313 |
| [10] | Cul Shuxiang, . Oncologic Emergency Radiation Therapy of Malignant Tumor[J]. Cancer Research on Prevention and Treatment, 1995, 22(2): 95-97. |
Tables(2)
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: